Want to see HK:6896 full AI Analyst Report?
Top Page
Golden Throat Holdings Group Co Ltd
(6896)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$3.00
▼(-2.28% Downside)
Action:Downgraded
Date:04/29/26
The score is driven primarily by financial performance: strong margins are offset by 2025’s pronounced cash-flow deterioration and weaker revenue, plus higher leverage. Valuation is a major positive (low P/E and very high dividend yield), while technical signals are neutral-to-mixed and do not materially add conviction.
Positive Factors
High margins
Sustained gross and net margins indicate durable pricing power and strong cost control in the core product line. High margins provide a structural cushion versus revenue swings, supporting reinvestment, dividend capacity, and resilience of profitability over the next several quarters.
Negative Factors
Sharp cash-flow drop
A large year-over-year collapse in operating and free cash flow materially reduces financial flexibility. It constrains reinvestment, dividend sustainability, and forces reliance on working-capital or external financing, elevating execution risk over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
High margins
Sustained gross and net margins indicate durable pricing power and strong cost control in the core product line. High margins provide a structural cushion versus revenue swings, supporting reinvestment, dividend capacity, and resilience of profitability over the next several quarters.
Read all positive factors
Golden Throat Holdings Group Co Ltd (6896) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.17B
Dividend Yield15.97%
Average Volume (3M)691.97K
Price to Earnings (P/E)7.7
Beta (1Y)0.20
Revenue Growth-20.14%
EPS Growth-20.91%
CountryHK
Employees874
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.33
Shares Outstanding739,302,000
10 Day Avg. Volume656,610
30 Day Avg. Volume691,973
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)1.47
Price to Sales (P/S)2.15
P/FCF Ratio25.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Golden Throat Holdings Group Co Ltd Business Overview & Revenue Model
Company Description
Golden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of Ch...
How the Company Makes Money
Golden Throat Holdings Group Co., Ltd. makes money primarily by selling branded throat lozenges and related products. Its core revenue stream comes from product sales under the Golden Throat brand to downstream customers (e.g., distributors, whole...
Golden Throat Holdings Group Co Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
70
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 943.26M | 1.19B | 961.38M | 992.01M | 820.54M |
| Gross Profit | 717.01M | 894.18M | 697.72M | 720.92M | 577.74M |
| EBITDA | 337.06M | 456.65M | 410.75M | 424.93M | 281.80M |
| Net Income | 251.20M | 318.63M | 250.16M | 281.22M | 187.64M |
Balance Sheet | |||||
| Total Assets | 2.29B | 2.25B | 2.30B | 2.30B | 1.95B |
| Cash, Cash Equivalents and Short-Term Investments | 1.08B | 1.14B | 1.07B | 925.51M | 802.84M |
| Total Debt | 584.52M | 426.92M | 412.34M | 272.59M | 235.00M |
| Total Liabilities | 912.77M | 784.87M | 748.34M | 760.18M | 588.04M |
| Stockholders Equity | 1.38B | 1.47B | 1.55B | 1.54B | 1.37B |
Cash Flow | |||||
| Free Cash Flow | 77.99M | 408.65M | 221.30M | 255.30M | 116.23M |
| Operating Cash Flow | 123.31M | 475.87M | 238.84M | 271.15M | 164.89M |
| Investing Cash Flow | -55.02M | -41.60M | -59.67M | 36.59M | -145.11M |
| Financing Cash Flow | -228.90M | -335.18M | -79.38M | -142.01M | -10.21M |
Golden Throat Holdings Group Co Ltd Technical Analysis
Negative
3.07
Price Trends
3.15
Negative
3.08
Negative
3.06
Negative
Market Momentum
-0.06
Positive
36.07
Neutral
7.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6896, the sentiment is Negative. The current price of 3.07 is below the 20-day moving average (MA) of 3.07, below the 50-day MA of 3.15, and above the 200-day MA of 3.06, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 36.07 is Neutral, neither overbought nor oversold. The STOCH value of 7.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6896.
Golden Throat Holdings Group Co Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | HK$747.94M | 8.00 | 12.80% | 7.52% | -9.66% | 16.17% | |
69 Neutral | HK$1.90B | 6.62 | 12.91% | 15.40% | -0.47% | -0.33% | |
68 Neutral | HK$2.17B | 7.71 | 19.22% | 15.97% | -20.14% | -20.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$6.75B | -17.08 | -1.66% | 3.66% | -10.68% | -737.07% | |
46 Neutral | HK$334.31M | 83.33 | -1.17% | 7.50% | -8.30% | -44.44% | |
45 Neutral | HK$155.13M | -3.39 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:6896
Golden Throat Holdings Group Co Ltd
2.94
-1.02
-25.74%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.34
-0.78
-36.94%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.30
-0.04
-11.76%
HK:1498
PuraPharm Corp. Ltd.
0.29
-0.20
-40.82%
HK:0239
Pak Fah Yeow International Limited
2.40
0.06
2.56%
HK:2633
Jacobson Pharma Corporation Limited
1.00
-0.47
-31.97%
Golden Throat Holdings Group Co Ltd Corporate Events
Golden Throat Wins Strong Shareholder Backing for Dividend, Mandates and Governance Changes
Jun 5, 2026
Golden Throat Holdings Group Co Ltd reported that all resolutions at its 5 June 2026 annual general meeting were approved by shareholders via poll, with full board attendance and no voting restrictions or abstentions required under Hong Kong listi...
Golden Throat Sets 2026 AGM to Approve Dividend, Auditor and Share Mandates
May 13, 2026
Golden Throat Holdings Group Co Ltd has convened its annual general meeting for 5 June 2026 in Hong Kong, where shareholders will be asked to receive and adopt the audited consolidated financial statements for the year ended 31 December 2025 and a...
Golden Throat to Modernize Articles, Enable Electronic and Hybrid Shareholder Meetings
May 11, 2026
Golden Throat Holdings Group Company Limited plans to update its constitutional documents by replacing its existing second amended and restated articles of association with a new, third amended and restated version. The changes are designed to ali...
Golden Throat Updates Timetable for 2025 Final Dividend Payout
Apr 27, 2026
Golden Throat Holdings Group Company Limited has updated its previously announced final dividend for the year ended 31 December 2025, confirming a payout of HKD 0.34 per share, subject to shareholder approval at a meeting scheduled for 5 June 2026...
Golden Throat Profit Falls Over 20% in 2025 but Dividend Maintained
Mar 27, 2026
Golden Throat Holdings reported a sharp deterioration in 2025 results, with revenue falling 20.4% year on year to RMB943.3 million and gross profit down 19.8% to RMB717.0 million. Earnings before interest, taxes, depreciation and amortisation drop...
Golden Throat Declares HKD 0.34 Final Dividend for 2025
Mar 27, 2026
Golden Throat Holdings Group Company Limited has declared a final ordinary cash dividend of HKD 0.34 per share for the financial year ended 31 December 2025, payable in Hong Kong dollars. Shareholder approval, ex-dividend date, book closure period...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.